title: How should we proceed with disease-modifying treatments for multiple sclerosis?
authors.affiliation: University of California San Francisco/Mt Zion Multiple Sclerosis Center 94115, USA.
authors.forename: P B
authors.initials: PB
authors.lastname: Andersson
authors.forename: E
authors.initials: E
authors.lastname: Waubant
authors.forename: D E
authors.initials: DE
authors.lastname: Goodkin
mesh_terms: D002986:Clinical Trials as Topic; D018450:Disease Progression; D000068717:Glatiramer Acetate; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000276:immunology / Q000628:therapy*; D010455:Peptides / Q000627:therapeutic use
chemical_list: D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D010455:Peptides; D000068576:Interferon beta-1b; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D000068556:Interferon beta-1a